US 12,029,721 B2
Compositions comprising cannabinoids and methods of use
George D. Pappas, Chicago, IL (US)
Assigned to Schedule 1 Therapeutics, Inc., Chicago, IL (US)
Filed by Schedule 1 Therapeutics, Inc., Chicago, IL (US)
Filed on Jun. 9, 2023, as Appl. No. 18/208,017.
Application 18/208,017 is a continuation of application No. 18/083,824, filed on Dec. 19, 2022, granted, now 11,712,431.
Application 18/083,824 is a continuation of application No. 17/707,542, filed on Mar. 29, 2022, granted, now 11,607,400, issued on Mar. 21, 2023.
Claims priority of provisional application 63/167,448, filed on Mar. 29, 2021.
Prior Publication US 2023/0355572 A1, Nov. 9, 2023
Int. Cl. A61K 31/352 (2006.01); A61K 31/05 (2006.01); A61K 45/06 (2006.01); A61P 25/04 (2006.01)
CPC A61K 31/352 (2013.01) [A61K 31/05 (2013.01); A61K 45/06 (2013.01); A61P 25/04 (2018.01)] 19 Claims
 
1. A method of treating migraine pain, the method comprising administering a composition comprising a pharmaceutically effective amount of CBD and THC to a subject in need thereof, thereby reducing migraine pain in the subject, wherein the weight ratio of CBD to THC is about 100:1.